SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropath.

Adája Elisabeth BaarsKrista KuitwaardLaura C de KoningLinda W G LuijtenW Maaike KokFilip EftimovLuuk WieskeH Stephan GoedeeLudo van der PolPatricia H Blomkwist-MarkensAnja M C HoremansBart C JacobsPieter A van Doorn

Published in: Neurology (2022)

We found no increased risk of GBS recurrence, and a low to negligible risk of worsening of CIDP or MMN related symptoms following SARS-CoV-2 vaccination. Based on our data, SARS-CoV-2 vaccination in patients with these immune-mediated neuropathies appears to be safe.

Keyphrases

sars cov
respiratory syndrome coronavirus
oxidative stress
electronic health record
big data
sleep quality
physical activity
drug induced
coronavirus disease
artificial intelligence